[HTML][HTML] Advances in radionuclides and radiolabelled peptides for cancer therapeutics
Radiopharmaceutical therapy, which can detect and treat tumours simultaneously, was
introduced more than 80 years ago, and it has changed medical strategies with respect to …
introduced more than 80 years ago, and it has changed medical strategies with respect to …
[PDF][PDF] Лучевая и радионуклидная визуализация в диагностике АКТГ-продуцирующих нейроэндокринных опухолей
В ОпуХОЛЕ - Медицинская радиология и радиационная …, 2022 - researchgate.net
АКТГ-эктопированный синдром, обусловленный избыточной продукцией
адренокортикотропного гормона (АКТГ) нейроэндокринной опухолью (НЭО), является …
адренокортикотропного гормона (АКТГ) нейроэндокринной опухолью (НЭО), является …
Improvements and future perspective in diagnostic tools for neuroendocrine neoplasms
S Massironi, M Franchina, D Ippolito… - Expert Review of …, 2024 - Taylor & Francis
ABSTRACT Introduction Neuroendocrine neoplasms (NENs) represent a complex group of
tumors arising from neuroendocrine cells, characterized by heterogeneous behavior and …
tumors arising from neuroendocrine cells, characterized by heterogeneous behavior and …
Primary neuroendocrine neoplasms of the kidney: a case report and literature review
C Liu, Y Qi, Y Zhang, X Yang - Journal of International …, 2023 - journals.sagepub.com
Primary kidney neuroendocrine tumors (NETs) are rare renal malignancies. However,
detecting and monitoring neuroendocrine neoplasms remains challenging because of their …
detecting and monitoring neuroendocrine neoplasms remains challenging because of their …
Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy
E O'Neill, B Cornelissen - Nuclear Medicine and Biology, 2022 - Elsevier
Molecular radionuclide therapy (MRT) is an effective treatment for both localised and
disseminated tumours. Biomarkers can be used to identify potential subtypes of tumours that …
disseminated tumours. Biomarkers can be used to identify potential subtypes of tumours that …
Molecular Imaging in neuroendocrine neoplasias
Molecular imaging, which uses molecular targets due to the overexpression of specific
peptide hormone receptors on the tumour surface, has become an indispensable diagnostic …
peptide hormone receptors on the tumour surface, has become an indispensable diagnostic …
[HTML][HTML] Outcome prediction of SSTR-RADS-3A and SSTR-RADS-3B lesions in patients with neuroendocrine tumors based on 68Ga-DOTATATE PET/MR
J Gao, J Zhou, C Liu, Y Pan, X Lin, Y Zhang - Journal of Cancer Research …, 2024 - Springer
Purpose Somatostatin receptor (SSTR)-targeted PET imaging has emerged as a common
approach to evaluating those patients with well-differentiated neuroendocrine tumors …
approach to evaluating those patients with well-differentiated neuroendocrine tumors …
Gastroduodenal neuroendocrine neoplasms including gastrinoma—update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of …
G Rydzewska, J Strzelczyk, T Bednarczuk… - Endokrynologia …, 2022 - journals.viamedica.pl
After anothe rm eeting of experts of the Polish Network of Neuroendocrine Tumours,
updated recommendations for th em anagement of patients with gastric and duodenal …
updated recommendations for th em anagement of patients with gastric and duodenal …
177Lu-DOTATATE (Lutathera) Therapy in 68Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor
D Ventura, W Roll, HU Kasper, K Rahbar… - Clinical Nuclear …, 2023 - journals.lww.com
A 73-year-old man with metastatic pancreatic neuroendocrine tumor was evaluated with 68
Ga-DOTATATE PET/CT for peptide receptor radionuclide therapy. Both PET-positive and …
Ga-DOTATATE PET/CT for peptide receptor radionuclide therapy. Both PET-positive and …
[HTML][HTML] Real-Life Use of [68Ga] Ga-DOTANOC PET/CT in Confirmed and Suspected NETs from a Prospective 5-Year Electronic Archive at an ENETS Center of …
N Bonazzi, E Fortunati, L Zanoni, G Argalia, D Calabrò… - Cancers, 2024 - mdpi.com
Simple Summary Neuroendocrine neoplasms'(NENs) rarity and heterogeneity represent a
clinical challenge. Somatostatin receptor (SST) positron emission tomography/computed …
clinical challenge. Somatostatin receptor (SST) positron emission tomography/computed …